ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 20 2 2 Combination with Pherecydes a nnounced , i ntending to c reate a g lobal l eader in e xtended p hage t herapies t argeting antimicrobial resistant p athogenic b acteria Deep restructuring
Monthly information related to total number of voting rights and shares composing the share capital _ January 3 1 , 202 3 . Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
Monthly information related to total number of voting rights and shares composing the share capital _ December 3 1 , 202 2 . Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
Monthly information related to total number of voting rights and shares composing the share capital _ Octobe r 3 0 , 202 2 . Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
Monthly information related to total number of voting rights and shares composing the share capital _ November 30 , 202 2 . Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
ERYTECH Provides Business and Financial Update for the Third Quarter of 20 2 2 Conference call and webcast on Tuesday, November 22, 2022 at 8:30am ET / 02:30pm CET Lead program Graspa halted F ocus on preclinical programs and partnering options Deep r estructuring implemented ; team size
ERYTECH Announces Receipt of N asdaq Notice Cambridge, MA (U.S.) and Lyon (France), October 1 3 , 202 2 – ERYTECH Pharma (Nasdaq & Euronext: a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today
Monthly information related to total number of voting rights and shares composing the share capital _ September 3 0 , 202 2 . Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C
ERYTECH Provides Business and Financial Update for the First Half of 20 2 2 Conference call and webcast on Tuesday, September 13, 2022 at 8:30am ET / 02:30pm CEST U.S. cell therapy manufacturing facility sold to Catalent in April 2022 Evaluation of partnering options ongoing, strategic
Monthly information related to total number of voting rights and shares composing the share capital _ Ju ly 3 1 , 202 2 . Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
